{"id":36475,"date":"2026-11-17T17:04:00","date_gmt":"2026-11-17T11:34:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=36475"},"modified":"2026-11-19T12:36:57","modified_gmt":"2026-11-19T07:06:57","slug":"pharma-news-for-jnj-astrazeneca-roche","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-jnj-astrazeneca-roche","title":{"rendered":"Johnson &amp; Johnson&#8217;s CAPLYTA Achieves Positive Results in Second Pivotal Phase 3 Bipolar Mania Study; US FDA Approves Klygefa for Adults with Generalised Myasthenia Gravis; Roche&#8217;s Gazyva\/Gazyvaro Secures First FDA Approval for Primary Membranous Nephropathy; Summit Therapeutics Provides Regulatory Update on Ivonescimab BLA; Novo Submits Etavopivat for Regulatory Approval as a Once-Daily Treatment for Sickle Cell Disease"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_85 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6afeae6cd712c\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6afeae6cd712c\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-jnj-astrazeneca-roche\/#Johnson_Johnson_Announces_Positive_Phase_3_Results_for_CAPLYTA_in_Bipolar_Mania\" >Johnson &amp; Johnson Announces Positive Phase 3 Results for CAPLYTA in Bipolar Mania<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-jnj-astrazeneca-roche\/#FDA_Approves_Klygefa_Gefurulimab_for_Adult_Generalised_Myasthenia_Gravis\" >FDA Approves Klygefa (Gefurulimab) for Adult Generalised Myasthenia Gravis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-jnj-astrazeneca-roche\/#FDA_Approves_Roches_GazyvaGazyvaro_as_the_First_Treatment_for_Primary_Membranous_Nephropathy\" >FDA Approves Roche&#8217;s Gazyva\/Gazyvaro as the First Treatment for Primary Membranous Nephropathy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-jnj-astrazeneca-roche\/#Summit_Therapeutics_Updates_on_Regulatory_Status_of_Ivonescimab_Biologics_License_Application\" >Summit Therapeutics Updates on Regulatory Status of Ivonescimab Biologics License Application<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-jnj-astrazeneca-roche\/#Novo_Nordisk_Submits_Etavopivat_for_FDA_and_EMA_Review_in_Adolescent_and_Adult_Sickle_Cell_Patients\" >Novo Nordisk Submits Etavopivat for FDA and EMA Review in Adolescent and Adult Sickle Cell Patients<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-johnson-amp-johnson-announces-positive-phase-3-results-for-caplyta-in-bipolar-mania\"><span class=\"ez-toc-section\" id=\"Johnson_Johnson_Announces_Positive_Phase_3_Results_for_CAPLYTA_in_Bipolar_Mania\"><\/span>Johnson &amp; Johnson Announces Positive Phase 3 Results for CAPLYTA in Bipolar Mania<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Johnson &amp; Johnson<\/strong> announced positive results from Study 452, the second pivotal Phase 3 trial assessing <strong>CAPLYTA (lumateperone)<\/strong> for the treatment of manic episodes, with or without mixed features, in <a href=\"https:\/\/www.delveinsight.com\/report-store\/bipolar-disorder-manic-depression-market\">adults with bipolar I disorder<\/a>. The study achieved both its primary and key secondary endpoints, demonstrating that CAPLYTA significantly reduced manic symptoms and overall disease severity compared with placebo at Week 3. Improvements were also evident as early as Day 3. The findings were presented as a late-breaking abstract at the <strong>2026 Neuroscience Education Institute (NEI) Fall Congress<\/strong>, held November 5\u20138 in Colorado Springs, Colorado.<\/p>\n\n\n\n<p>Combined with the previously reported positive outcomes from Study 451, the results establish consistent efficacy across two pivotal Phase 3 trials and are expected to support the company&#8217;s planned regulatory submission in the United States.<\/p>\n\n\n\n<p><em>According to Jane Tiller, FRCPsych, Vice President and Global Head of Development, Neuroscience, at Johnson &amp; Johnson, manic episodes can rapidly affect patients&#8217; safety, personal relationships, and everyday functioning, highlighting the importance of therapies that provide prompt symptom relief. She noted that the positive and consistent findings across both Phase 3 studies, together with CAPLYTA&#8217;s established safety and efficacy in bipolar I and II depression, reinforce its potential to help manage acute manic symptoms and stabilize patients during challenging phases of the disease.<\/em><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-approves-klygefa-gefurulimab-for-adult-generalised-myasthenia-gravis\"><span class=\"ez-toc-section\" id=\"FDA_Approves_Klygefa_Gefurulimab_for_Adult_Generalised_Myasthenia_Gravis\"><\/span>FDA Approves Klygefa (Gefurulimab) for Adult Generalised Myasthenia Gravis<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Alexion<\/strong>, AstraZeneca Rare Disease, announced that the US Food and Drug Administration (FDA) has approved <strong>Klygefa (gefurulimab)<\/strong> for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/generalized-myasthenia-gravis-gmg-market\">treatment of adult patients with generalised myasthenia gravis (gMG)<\/a> who are positive for anti-acetylcholine receptor (AChR) antibodies. Klygefa is the first and only dual-binding nanobody C5 inhibitor and is administered subcutaneously once weekly, allowing patients to self-administer the treatment using an autoinjector.<\/p>\n\n\n\n<p>The FDA approval was supported by positive findings from the pivotal Phase III PREVAIL trial. The study achieved its primary endpoint, demonstrating a statistically significant improvement from baseline in the Myasthenia Gravis Activities of Daily Living (MG-ADL) total score at week 26 compared with placebo. The treatment difference was -1.6 (95% CI: -2.4, -0.8; p&lt;0.0001). Furthermore, improvements in clinical outcomes were evident as early as the first week of treatment, in addition to the prespecified results at week 26.&nbsp;<\/p>\n\n\n\n<p>Generalised myasthenia gravis is a rare autoimmune condition characterised by impaired muscle function and significant muscle weakness. An estimated 98,500 people in the US are affected by gMG, of whom approximately 81,000 are AChR-antibody positive.<\/p>\n\n\n\n<p><em>According to Kelly Gwathmey, MD, associate professor in the Division of Neuromuscular Medicine within the Department of Neurology at Columbia University Vagelos College of Physicians and Surgeons, a member of the MGFA Medical &amp; Scientific Advisory Council, and a principal investigator in the PREVAIL trial at Virginia Commonwealth University, gMG is characterised by unpredictable and variable disease manifestations, making early intervention and consistent disease management important treatment objectives. She noted that gefurulimab demonstrated rapid and sustained improvements in physical functioning in the PREVAIL Phase III study while offering the convenience of once-weekly, self-administered subcutaneous injections. The US approval provides patients with a targeted treatment alternative that combines greater treatment autonomy with the established therapeutic benefits of C5 complement inhibition.<\/em><\/p>\n\n\n\n<p>Klygefa demonstrated a generally favourable tolerability profile, consistent with the safety experience previously reported for C5 inhibitors such as eculizumab and ravulizumab in gMG. The incidence of treatment-emergent adverse events (TEAEs) was comparable between the Klygefa and placebo groups, with most reported events being mild to moderate in severity (Grade 1 or 2). The most frequently reported TEAEs among Klygefa-treated patients were injection-site reactions (12%), back pain (8%) and vomiting (5%).<\/p>\n\n\n\n<p>Findings from the <strong>PREVAIL trial<\/strong> were presented at the Myasthenia Gravis Foundation of America (MGFA) Scientific Session during the <strong>American Association of Neuromuscular &amp; Electrodiagnostic Medicine (AANEM) 2025 Annual Meeting<\/strong>. The results were also published in JAMA Neurology. In addition to the US, Klygefa has received approval in the European Union, Japan, and several other markets for the treatment of certain adult patients with gMG. Regulatory applications supported by the PREVAIL trial results are currently under review in China and other countries.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-approves-roche-s-gazyva-gazyvaro-as-the-first-treatment-for-primary-membranous-nephropathy\"><span class=\"ez-toc-section\" id=\"FDA_Approves_Roches_GazyvaGazyvaro_as_the_First_Treatment_for_Primary_Membranous_Nephropathy\"><\/span>FDA Approves Roche&#8217;s Gazyva\/Gazyvaro as the First Treatment for Primary Membranous Nephropathy<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Roche <\/strong>announced that the US Food and Drug Administration (FDA) has approved <strong>Gazyva\/Gazyvaro (obinutuzumab)<\/strong> for treating <a href=\"https:\/\/www.delveinsight.com\/report-store\/membranous-nephropathy-market\">adults with primary membranous nephropathy (pMN)<\/a> who are at risk of disease progression, with the aim of inducing proteinuria remission. With this decision, Gazyva\/Gazyvaro becomes the first and only FDA-approved treatment for pMN, having previously received Breakthrough Therapy Designation. Primary membranous nephropathy is a chronic autoimmune condition that can result in kidney failure and imposes a significant clinical, economic and social burden on patients, caregivers and healthcare systems. Proteinuria, characterised by elevated levels of protein in the urine, is an important indicator of kidney damage.<\/p>\n\n\n\n<p><em>According to Levi Garraway, MD, PhD, Roche\u2019s Chief Medical Officer and Head of Global Product Development, the FDA approval marks a significant advancement for individuals with pMN, as targeting B cells addresses a key underlying mechanism of the disease. He highlighted that Roche\u2019s specialised antibody-engineering capabilities have translated into meaningful clinical benefits for patients with immune-mediated kidney disorders. He further noted that Gazyva\/Gazyvaro demonstrated substantially higher complete remission rates than tacrolimus, providing a more effective treatment approach for achieving sustained disease control.<\/em><\/p>\n\n\n\n<p>The FDA&#8217;s decision was supported by positive findings from the Phase III MAJESTY study, which achieved its primary endpoint. At 104 weeks, complete remission of proteinuria was observed in 36.1% of patients receiving Gazyva\/Gazyvaro, compared with 5.7% of those treated with tacrolimus (adjusted difference: 31.1%; 95% CI: 18.2\u201344.0; p&lt;0.001). The therapy also demonstrated superiority across key secondary endpoints. Overall remission, comprising complete or partial remission, at week 104 was achieved by 50% of patients in the Gazyva\/Gazyvaro group versus 12.9% in the tacrolimus group (adjusted difference: 37.8%; 95% CI: 23.9\u201351.8; p&lt;0.001). Similarly, complete remission at week 76 was reported in 36.1% and 8.6% of patients, respectively (adjusted difference: 27.4%; 95% CI: 13.4\u201339.8; p&lt;0.001). The safety findings were consistent with the established safety profile of Gazyva\/Gazyvaro, with no new safety concerns identified. Results from MAJESTY were presented as a late-breaking oral presentation at the 63rd European Renal Association (ERA) Congress in June 2026 and published in the New England Journal of Medicine (NEJM). Roche is also submitting the study findings to other international regulatory authorities, including the European Medicines Agency (EMA).<\/p>\n\n\n\n<p>This marks the third FDA approval of Gazyva\/Gazyvaro for an immune-mediated kidney disease, following its previous approvals for idiopathic nephrotic syndrome (INS) and lupus nephritis (LN). The FDA is also reviewing the <a href=\"https:\/\/www.delveinsight.com\/report-store\/systemic-lupus-erythematosus-market\">therapy for treating adults with systemic lupus erythematosus (SLE)<\/a>, with a regulatory decision anticipated by December 2026. In Europe, the EMA&#8217;s Committee for Medicinal Products for Human Use (CHMP) has recently issued a positive opinion recommending Gazyva\/Gazyvaro for adult patients with SLE, while the European Commission&#8217;s final decision is expected shortly. In addition to Gazyva\/Gazyvaro, Roche continues to advance a broad immunology pipeline focused on developing innovative treatments for immune-mediated conditions, including kidney diseases.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-summit-therapeutics-updates-on-regulatory-status-of-ivonescimab-biologics-license-application\"><span class=\"ez-toc-section\" id=\"Summit_Therapeutics_Updates_on_Regulatory_Status_of_Ivonescimab_Biologics_License_Application\"><\/span>Summit Therapeutics Updates on Regulatory Status of Ivonescimab Biologics License Application<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Summit Therapeutics Inc.<\/strong> announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) seeking approval of <strong>ivonescimab<\/strong> in combination with platinum-based chemotherapy for patients with locally advanced or <a href=\"https:\/\/www.delveinsight.com\/report-store\/epidermal-growth-factor-receptor-non-small-cell-lung-cancer-market\">metastatic non-small cell lung cancer (NSCLC)<\/a> previously treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). Ivonescimab is a novel bispecific antibody targeting PD-1 and VEGF. According to the CRL, the application cannot be approved in its current form because the FDA concluded that substantial evidence of effectiveness had not been established without a statistically significant improvement in overall survival (OS). The agency further noted that the progression-free survival (PFS) benefit, in the absence of a statistically significant OS improvement, was insufficient to demonstrate a favorable benefit-risk profile to support approval.<\/p>\n\n\n\n<p>At present, no FDA-approved treatment regimens in this patient population have demonstrated a statistically significant OS benefit. In the primary OS analysis, ivonescimab combined with chemotherapy showed a favorable trend, although the results did not reach statistical significance. However, a post-hoc analysis based on extended follow-up of Western patients indicated a consistent OS benefit across geographical subgroups, with a hazard ratio of 0.76 reported in the overall population, Asian patients, and Western patients.<\/p>\n\n\n\n<p>The BLA was primarily supported by findings from <strong>HARMONi<\/strong>, a global, randomized, double-blind Phase III clinical trial comparing ivonescimab plus platinum-based chemotherapy with placebo plus platinum-based chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who had previously received a third-generation EGFR TKI. The study included two primary endpoints: PFS and OS. HARMONi achieved its primary PFS endpoint, marking the first global Phase III trial of an immunotherapy-based treatment regimen to demonstrate a statistically significant improvement in PFS in this patient population. The primary PFS findings were further supported by a post-hoc analysis incorporating longer-term follow-up, which confirmed a consistent magnitude of treatment benefit with more mature data from Western patients.<\/p>\n\n\n\n<p>The combination of ivonescimab and chemotherapy exhibited an acceptable and manageable safety profile, consistent with findings from previous clinical studies. The treatment was generally well tolerated, with no new safety signals identified and comparable discontinuation and treatment-related mortality rates across the study arms. Treatment-related adverse events (TRAEs) led to discontinuation of ivonescimab in 16 patients (7.3%), compared with 11 patients (5.0%) receiving placebo. Additionally, TRAE-related deaths were reported in four patients (1.8%) in the ivonescimab plus chemotherapy arm and five patients (2.3%) in the chemotherapy-alone arm.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-novo-nordisk-submits-etavopivat-for-fda-and-ema-review-in-adolescent-and-adult-sickle-cell-patients\"><span class=\"ez-toc-section\" id=\"Novo_Nordisk_Submits_Etavopivat_for_FDA_and_EMA_Review_in_Adolescent_and_Adult_Sickle_Cell_Patients\"><\/span>Novo Nordisk Submits Etavopivat for FDA and EMA Review in Adolescent and Adult Sickle Cell Patients<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Novo Nordisk<\/strong> announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for <strong>etavopivat<\/strong>, an investigational, once-daily, orally administered selective activator of the red blood cell pyruvate kinase isozyme (PKR). The drug is being developed for the treatment of adolescents and adults aged 12 years and older with <a href=\"https:\/\/www.delveinsight.com\/report-store\/sickle-cell-disease-6mm-market\">sickle cell disease (SCD)<\/a>. If approved, etavopivat could introduce a novel disease-modifying therapeutic approach for managing SCD.<\/p>\n\n\n\n<p>Etavopivat has previously received <strong>Fast Track, Rare Pediatric Disease, and Orphan Drug designations<\/strong> from the FDA, which is expected to issue its decision on the NDA in 2027. Additionally, the European Commission has granted the drug Orphan Drug designation, with regulatory action on the MAA also anticipated in 2027. The MAA represents the formal application seeking authorization to commercialize a medicinal product within the European Union (EU).<\/p>\n\n\n\n<p><em>According to Martin Holst Lange, executive vice president, chief scientific officer and head of Research &amp; Development at Novo Nordisk, sickle cell disease significantly affects patients&#8217; daily lives through severe vaso-occlusive crises (VOCs) and other disease-related symptoms, while available treatment options remain limited. He expressed optimism that, if approved, etavopivat could provide a new disease-modifying treatment alternative for individuals living with SCD. He also emphasized the company&#8217;s commitment to collaborating with the SCD community to promote health equity and address persistent disparities affecting patients with the disease.<\/em><\/p>\n\n\n\n<p>The regulatory submissions are supported by findings from the <strong>HIBISCUS clinical study program<\/strong>, which assessed the efficacy and safety of etavopivat in adults and adolescents with SCD. The trials evaluated the annualized rate of VOCs through week 52 and the proportion of patients achieving a haemoglobin increase of greater than 1 g\/dL at week 24, compared with placebo. Participants were permitted to continue receiving standard-of-care treatments throughout the study. According to topline results reported in April 2026, etavopivat demonstrated a 27% reduction in VOCs and delayed the occurrence of the first VOC by approximately four months compared with placebo. Further detailed findings from the Phase III HIBISCUS trial are expected to be presented at an upcoming scientific conference and published in a peer-reviewed journal.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Johnson &amp; Johnson Announces Positive Phase 3 Results for CAPLYTA in Bipolar Mania Johnson &amp; Johnson announced positive results from Study 452, the second pivotal Phase 3 trial assessing CAPLYTA (lumateperone) for the treatment of manic episodes, with or without mixed features, in adults with bipolar I disorder. The study achieved both its primary and [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":36476,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[22034,23191,349,6733,639,22893,536],"industry":[17225],"therapeutic_areas":[17233,17245,17228],"class_list":["post-36475","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-bipolar-i-disorder","tag-generalised-myasthenia-gravis","tag-latest-pharma-news","tag-non-small-cell-lung-cancer","tag-pharma-news","tag-primary-membranous-nephropathy","tag-sickle-cell-disease","industry-pharmaceutical","therapeutic_areas-hematological-disorders","therapeutic_areas-neurology","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.9 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Pharma News | Johnson &amp; Johnson, AstraZeneca, Roche<\/title>\n<meta name=\"description\" content=\"Johnson &amp; Johnson\u2019s CAPLYTA; AstraZeneca\u2019s Klygefa; Roche\u2019s Gazyva; Summit Therapeutics\u2019 Ivonescimab; Novo\u2019s Etavopivat\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-jnj-astrazeneca-roche\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Johnson &amp; Johnson, AstraZeneca, Roche\" \/>\n<meta property=\"og:description\" content=\"Johnson &amp; Johnson\u2019s CAPLYTA; AstraZeneca\u2019s Klygefa; Roche\u2019s Gazyva; Summit Therapeutics\u2019 Ivonescimab; Novo\u2019s Etavopivat\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-jnj-astrazeneca-roche\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-17T11:34:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-19T07:06:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/pharma-news-for-jnj-astrazeneca-roche.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Johnson & Johnson, AstraZeneca, Roche","description":"Johnson & Johnson\u2019s CAPLYTA; AstraZeneca\u2019s Klygefa; Roche\u2019s Gazyva; Summit Therapeutics\u2019 Ivonescimab; Novo\u2019s Etavopivat","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-jnj-astrazeneca-roche","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Johnson & Johnson, AstraZeneca, Roche","og_description":"Johnson & Johnson\u2019s CAPLYTA; AstraZeneca\u2019s Klygefa; Roche\u2019s Gazyva; Summit Therapeutics\u2019 Ivonescimab; Novo\u2019s Etavopivat","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-jnj-astrazeneca-roche","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2026-11-17T11:34:00+00:00","article_modified_time":"2026-11-19T07:06:57+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/pharma-news-for-jnj-astrazeneca-roche.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-jnj-astrazeneca-roche#article","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-jnj-astrazeneca-roche"},"author":{"name":"Sandeep Joshi","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"headline":"Johnson &amp; Johnson&#8217;s CAPLYTA Achieves Positive Results in Second Pivotal Phase 3 Bipolar Mania Study; US FDA Approves Klygefa for Adults with Generalised Myasthenia Gravis; Roche&#8217;s Gazyva\/Gazyvaro Secures First FDA Approval for Primary Membranous Nephropathy; Summit Therapeutics Provides Regulatory Update on Ivonescimab BLA; Novo Submits Etavopivat for Regulatory Approval as a Once-Daily Treatment for Sickle Cell Disease","datePublished":"2026-11-17T11:34:00+00:00","dateModified":"2026-11-19T07:06:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-jnj-astrazeneca-roche"},"wordCount":1987,"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-jnj-astrazeneca-roche#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/pharma-news-for-jnj-astrazeneca-roche.webp","keywords":["bipolar I disorder","Generalised Myasthenia Gravis","Latest pharma news","Non-small cell lung cancer","pharma news","primary membranous nephropathy","sickle cell disease"],"articleSection":["Notizia - Recent Pharma, Healthcare and Biotech Happenings"],"inLanguage":"en-US","copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/www.delveinsight.com\/blog\/#organization"}},{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-jnj-astrazeneca-roche","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-jnj-astrazeneca-roche","name":"Pharma News | Johnson & Johnson, AstraZeneca, Roche","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-jnj-astrazeneca-roche#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-jnj-astrazeneca-roche#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/pharma-news-for-jnj-astrazeneca-roche.webp","datePublished":"2026-11-17T11:34:00+00:00","dateModified":"2026-11-19T07:06:57+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Johnson & Johnson\u2019s CAPLYTA; AstraZeneca\u2019s Klygefa; Roche\u2019s Gazyva; Summit Therapeutics\u2019 Ivonescimab; Novo\u2019s Etavopivat","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-jnj-astrazeneca-roche"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-jnj-astrazeneca-roche#primaryimage","url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/pharma-news-for-jnj-astrazeneca-roche.webp","contentUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/pharma-news-for-jnj-astrazeneca-roche.webp","width":772,"height":482,"caption":"pharma-news-for-jnj-astrazeneca-roche"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/pharma-news-for-jnj-astrazeneca-roche-300x187.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">bipolar I disorder<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Generalised Myasthenia Gravis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Non-small cell lung cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">primary membranous nephropathy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">sickle cell disease<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">bipolar I disorder<\/span>","<span class=\"advgb-post-tax-term\">Generalised Myasthenia Gravis<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">Non-small cell lung cancer<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">primary membranous nephropathy<\/span>","<span class=\"advgb-post-tax-term\">sickle cell disease<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 days ago","modified":"Updated 4 hours ago"},"absolute_dates":{"created":"Posted on Nov 17, 2026","modified":"Updated on Nov 19, 2026"},"absolute_dates_time":{"created":"Posted on Nov 17, 2026 5:04 pm","modified":"Updated on Nov 19, 2026 12:36 pm"},"featured_img_caption":"pharma-news-for-jnj-astrazeneca-roche","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/36475","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=36475"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/36475\/revisions"}],"predecessor-version":[{"id":36477,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/36475\/revisions\/36477"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/36476"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=36475"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=36475"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=36475"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=36475"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=36475"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}